Recent research has focused on enhancing the efficacy of glioma treatments through innovative therapeutic strategies. One study investigated the potential of meloxicam, a non-steroidal anti-inflammatory drug (NSAID), to augment the effects of synchrotron microbeam radiation therapy (MRT) in high-grade glioma-bearing rats. The study demonstrated that combining meloxicam with MRT, which utilizes spatially micro-fractionated radiation, significantly improved survival rates compared to MRT alone. Specifically, rats treated with a combination of meloxicam and MRT (400 Gy, with 50 µm-wide microbeams and 200 µm spacing) showed a marked increase in therapeutic response, suggesting that NSAIDs may play a crucial role in enhancing the effectiveness of advanced radiation therapies (ref: Bouchet doi.org/10.1667/RADE-21-00107.1/). Another study explored the radiation responses of cancer and normal cells to different dose fractionation strategies, specifically comparing uniform and grid fields. The findings indicated that a medium delay in treatment with a grid field significantly increased toxicity across four cancer cell lines, while a uniform field showed increased toxicity in two prostate cancer cell lines. This suggests that optimizing dose fractionation and timing can enhance the therapeutic ratio, potentially leading to improved outcomes in glioma treatment (ref: Rogers doi.org/10.1080/09553002.2022.2047826/). Together, these studies highlight the importance of combining pharmacological agents with advanced radiation techniques to improve treatment efficacy in glioma patients.